Castle Biosciences (CSTL) Assets Average (2019 - 2026)

Castle Biosciences has reported Assets Average for 8 years, with the latest figure at $554.5 million in Q2 2026.

• Quarterly Assets Average rose 5.98% year-over-year to $554.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $554.5 million (up 5.98% YoY) and the FY2025 annual result came in at $554.9 million, up 12.72% from the prior year.
• Assets Average declined to $554.5 million in Q2 2026 per CSTL's latest filing, from $563.2 million in the prior quarter.
• Over five years, Assets Average peaked at $570.7 million in Q4 2025 and troughed at $426.1 million in Q2 2023.
• A 5-year average of $488.3 million and a median of $465.5 million in 2022 frame the typical range for Assets Average.
• The sharpest annual moves came in 2023 and 2024: Assets Average dropped 5.98% in 2023, then gained 17.59% in 2024.
• Over 5 years, Assets Average stood at $452.6 million in 2022, then decreased by 1.74% to $444.7 million in 2023, then grew by 17.59% to $522.9 million in 2024, then rose by 9.14% to $570.7 million in 2025, then decreased by 2.84% to $554.5 million in 2026.
• According to Business Quant data, Assets Average over the past three periods registered $554.5 million, $563.2 million, and $570.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.